Shattuck Labs Inc
STTK3.770USD
+0.200+5.60%
終値 02/06, 16:00（ET）15分遅れの株価
238.08M時価総額
損失額直近12ヶ月PER
詳細情報 Shattuck Labs Inc 企業名
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Incの企業情報
企業コードSTTK
会社名Shattuck Labs Inc
上場日Oct 09, 2020
最高経営責任者「CEO」Schreiber (Taylor)
従業員数44
証券種類Ordinary Share
決算期末Oct 09
本社所在地500 W. 5Th Street
都市AUSTIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号78701
電話番号15129004690
ウェブサイトhttps://www.shattucklabs.com/
企業コードSTTK
上場日Oct 09, 2020
最高経営責任者「CEO」Schreiber (Taylor)
Shattuck Labs Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Fri, Jan 30
更新時刻: Fri, Jan 30
株主統計
種類
株主統計
株主統計
比率
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Hornblower Capital Holdings, LLC
4.57%
他の
58.13%
株主統計
株主統計
比率
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Hornblower Capital Holdings, LLC
4.57%
他の
58.13%
種類
株主統計
比率
Hedge Fund
23.34%
Investment Advisor/Hedge Fund
14.68%
Private Equity
9.97%
Corporation
9.51%
Investment Advisor
6.66%
Family Office
2.58%
Research Firm
2.11%
Individual Investor
1.80%
Venture Capital
0.04%
他の
29.31%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
186
35.95M
56.82%
+4.07M
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
OrbiMed Advisors, LLC
6.31M
9.97%
+6.31M
--
Sep 30, 2025
Adage Capital Management, L.P.
6.31M
9.97%
+1.63M
+34.89%
Sep 30, 2025
Redmile Group, LLC
5.54M
8.75%
--
--
Sep 30, 2025
Prosight Capital
5.45M
8.61%
-1.19M
-17.89%
Sep 30, 2025
Hornblower Capital Holdings, LLC
2.89M
4.57%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
4.13%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.13M
3.36%
-19.77K
-0.92%
Sep 30, 2025
683 Capital Management LLC
1.53M
2.42%
+437.22K
+39.93%
Sep 30, 2025
The Clark Estates Inc.
1.48M
2.33%
--
--
Sep 30, 2025
Pinnacle Associates Ltd.
1.39M
2.19%
+25.00K
+1.83%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
詳細を見る
Texas Capital Texas Equity Index ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
ProShares UltraPro Russell2000
比率0%
Dimensional US Core Equity 1 ETF
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Morningstar Small-Cap ETF
比率0%
iShares Russell 2000 ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
iShares Micro-Cap ETF
比率0%
Texas Capital Texas Small Cap Equity Index ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
